Literature DB >> 21496875

Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma.

Nobuhiro Fujita1, Shinichi Aishima, Tomohiro Iguchi, Yohei Mano, Akinobu Taketomi, Ken Shirabe, Hiroshi Honda, Masazumi Tsuneyoshi, Yoshinao Oda.   

Abstract

Portal venous invasion is one of the most important prognostic factors after surgical resection of hepatocellular carcinoma. Microscopic portal venous invasion can be evaluated histologically. We examined 280 hepatocellular carcinomas with microscopic portal venous invasion (n = 125) or without it (n = 155) for 3 characteristics: the number of invaded portal vessels, the maximum number of invading carcinoma cells, and the farthest distance from the tumor. Univariate analysis of overall and disease-free survival revealed that the number of invaded portal vessels and the number of invading carcinoma cells were poor prognostic factors. Therefore, we classified patients with microscopic portal venous invasion into 2 groups: a high-microscopic portal venous invasion group, in which there were multiple invaded portal venous vessels (≥2) and more than 50 invading carcinoma cells (n = 57), and a low-microscopic portal venous invasion group, in which microscopic portal venous invasion was observed but with invasion of only a single portal venous vessel or fewer than 50 invading carcinoma cells (n = 68). The high-microscopic portal venous invasion group showed significantly higher α-fetoprotein levels, larger tumor size, and higher frequencies of poorly differentiated histology, capsule infiltration, and intrahepatic metastasis compared with the low-microscopic portal venous invasion group (P = .0496, P < .0001, P = .0431, P = .0180, and P = .0012, respectively). The high-microscopic portal venous invasion group showed poorer overall survival and disease-free survival rates than the low-microscopic portal venous invasion group (P = .0004 and P = .0003), and the high-microscopic portal venous invasion group was an independent prognostic factor for disease-free survival (P = .0259). We proposed a new definition for classifying microscopic portal venous invasion and documented the necessity of definite histologic evaluation of it.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21496875     DOI: 10.1016/j.humpath.2010.12.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.

Authors:  Xia Sheng; Yuan Ji; Guo-Ping Ren; Chang-Li Lu; Jing-Ping Yun; Li-Hong Chen; Bin Meng; Li-Juan Qu; Guang-Jie Duan; Qing Sun; Xin-Qing Ye; Shan-Shan Li; Jing Yang; Bing Liao; Zhan-Bo Wang; Jian-Hua Zhou; Yu Sun; Xue-Shan Qiu; Lei Wang; Zeng-Shan Li; Jun Chen; Chun-Yan Xia; Song He; Chuan-Ying Li; En-Wei Xu; Jing-Shu Geng; Chao Pan; Dong Kuang; Rong Qin; Hong-Wei Guan; Zhan-Dong Wang; Li-Xing Li; Xi Zhang; Han Wang; Qian Zhao; Bo Wei; Wu-Jian Zhang; Shao-Ping Ling; Xiang Du; Wen-Ming Cong
Journal:  Hepatol Int       Date:  2020-12-28       Impact factor: 6.047

2.  Clinicopathological Characteristics of Hepatocellular Carcinoma with Microscopic Portal Venous Invasion and the Role of Anatomical Liver Resection in These Cases.

Authors:  Shingo Shimada; Toshiya Kamiyama; Hideki Yokoo; Tatsuya Orimo; Kenji Wakayama; Takahiro Einama; Tatsuhiko Kakisaka; Hirofumi Kamachi; Akinobu Taketomi
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

Review 3.  Reappraisal of evidence of microscopic portal vein involvement by hepatocellular carcinoma cells with stratification of tumor size.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

4.  Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion.

Authors:  Yiwen Qiu; Yi Yang; Tao Wang; Shu Shen; Wentao Wang
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

5.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

6.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

7.  Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma.

Authors:  Xubiao Wei; Nan Li; Shanshan Li; Jie Shi; Weixing Guo; Yaxin Zheng; Shuqun Cheng
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

8.  Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection.

Authors:  Hui Zhao; Chuang Chen; Xu Fu; Xiaopeng Yan; Wenjun Jia; Liang Mao; Huihan Jin; Yudong Qiu
Journal:  Oncotarget       Date:  2017-01-17

9.  Angelicin inhibits liver cancer growth in vitro and in vivo.

Authors:  Fengliang Wang; Jun Li; Rong Li; Guohua Pan; Mingxia Bai; Qiang Huang
Journal:  Mol Med Rep       Date:  2017-08-10       Impact factor: 2.952

10.  Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report.

Authors:  Toru Hirozane; Robert Nakayama; Sayaka Yamaguchi; Tomoaki Mori; Naofumi Asano; Keisuke Asakura; Kazutaka Kikuta; Miho Kawaida; Aya Sasaki; Hajime Okita; Seishi Nakatsuka; Tsutomu Ito
Journal:  World J Surg Oncol       Date:  2022-01-07       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.